Janney Montgomery Scott LLC decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 168,285 shares of the biopharmaceutical company’s stock after selling 8,089 shares during the period. Janney Montgomery Scott LLC’s holdings in Gilead Sciences were worth $12,993,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also modified their holdings of GILD. Bank of New York Mellon Corp increased its holdings in shares of Gilead Sciences by 11.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 30,936,970 shares of the biopharmaceutical company’s stock valued at $2,191,575,000 after purchasing an additional 3,221,439 shares during the period. Swedbank increased its holdings in shares of Gilead Sciences by 103.7% in the 3rd quarter. Swedbank now owns 3,906,172 shares of the biopharmaceutical company’s stock valued at $301,596,000 after purchasing an additional 1,988,987 shares during the period. Natixis increased its holdings in shares of Gilead Sciences by 4,550.6% in the 2nd quarter. Natixis now owns 1,913,535 shares of the biopharmaceutical company’s stock valued at $135,555,000 after purchasing an additional 1,872,389 shares during the period. Los Angeles Capital Management & Equity Research Inc. increased its holdings in shares of Gilead Sciences by 1,631.7% in the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 997,656 shares of the biopharmaceutical company’s stock valued at $70,674,000 after purchasing an additional 940,044 shares during the period. Finally, Sanders Capital LLC increased its holdings in Gilead Sciences by 7.0% in the second quarter. Sanders Capital LLC now owns 10,579,575 shares of the biopharmaceutical company’s stock worth $804,126,000 after buying an additional 696,200 shares during the last quarter. Institutional investors own 78.09% of the company’s stock.
GILD has been the topic of a number of research reports. Piper Jaffray Companies set a $85.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a report on Wednesday, September 12th. Mizuho restated a “buy” rating and issued a $94.00 price objective on shares of Gilead Sciences in a report on Friday, August 10th. Zacks Investment Research upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $86.00 price objective on the stock in a report on Wednesday, July 18th. BidaskClub upgraded Gilead Sciences from a “hold” rating to a “buy” rating in a report on Thursday, October 11th. Finally, Evercore ISI restated a “buy” rating on shares of Gilead Sciences in a report on Wednesday, October 31st. Twelve investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $87.84.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.63 by $0.21. The firm had revenue of $5.60 billion during the quarter, compared to analysts’ expectations of $5.44 billion. Gilead Sciences had a return on equity of 39.32% and a net margin of 7.12%. During the same quarter in the prior year, the business earned $2.27 earnings per share. As a group, equities analysts predict that Gilead Sciences, Inc. will post 6.44 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, December 28th. Shareholders of record on Friday, December 14th will be given a dividend of $0.57 per share. The ex-dividend date of this dividend is Thursday, December 13th. This represents a $2.28 dividend on an annualized basis and a yield of 3.20%. Gilead Sciences’s payout ratio is currently 26.64%.
In other Gilead Sciences news, Director John C. Martin sold 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 4th. The stock was sold at an average price of $74.16, for a total transaction of $3,708,000.00. Following the completion of the sale, the director now owns 3,067,762 shares of the company’s stock, valued at $227,505,229.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 150,000 shares of company stock valued at $11,087,500 in the last ninety days. Company insiders own 1.30% of the company’s stock.
Gilead Sciences Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Read More: Why do companies issue stock splits?
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.